BlueCrest Capital Management’s Biogen BIIB Stock Holding History

BlueCrest Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-7,384	Closed	-$1.72M	–	407
2019 Q3	$1.72M	Buy	+7,384	New	+$1.72M	0.12%	136
2019 Q2	–	Sell	-8,885	Closed	-$2.1M	–	471
2019 Q1	$2.1M	Buy	+8,885	New	+$2.8M	0.08%	171
2018 Q4	–	Sell	-21,022	Closed	-$7.43M	–	892
2018 Q3	$7.43M	Buy	+21,022	New	+$7.24M	0.2%	74
2018 Q1	–	Sell	-50,461	Closed	-$16.1M	–	1481
2017 Q4	$16.1M	Buy	+50,461	New	+$16.2M	0.44%	38
2016 Q3	–	Sell	-905	Closed	-$219K	–	751
2016 Q2	$219K	Buy	+905	New	+$239K	0.01%	767
2016 Q1	–	Sell	-2,629	Closed	-$805K	–	787
2015 Q4	$805K	Buy	+2,629	New	+$755K	0.03%	467
2015 Q2	–	Sell	-675	Closed	-$285K	–	791
2015 Q1	$285K	Sell	675 -420	-38%	-$166K	0.02%	529
2014 Q4	$372K	Buy	1,095 +421	+62%	+$136K	0.01%	477
2014 Q3	$223K	Buy	+674	New	+$222K	0.01%	474

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BlueCrest Capital Management's BIIB Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Biogen (BIIB) in Q4 2019, closing a stake of 7,384 shares — an estimated $1.72M sold.

BlueCrest Capital Management first reported a position in BIIB in Q3 2014 and held it in 9 quarters. The position peaked at $16.1M in Q4 2017. 1,103 funds tracked by Wall St. Rank hold BIIB as of Q4 2019.

BlueCrest Capital Management reported no remaining Biogen position as of Q4 2019 after selling out during the quarter.
BlueCrest Capital Management sold 7,384 Biogen shares in Q4 2019, an estimated $1.72M.
BlueCrest Capital Management first reported a position in Biogen in Q3 2014 and held it in 9 quarters.
BlueCrest Capital Management's Biogen position peaked at $16.1M in Q4 2017.
1,103 funds tracked by Wall St. Rank held Biogen as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.